AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 36 min read$MED

MEDIFAST INC (MED): Results of Operations and Financial Condition

MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter

Original reporting
SEC EDGAR 8-K
Published Aug 3, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MED
Bearish
high confidence
Mentioned
$MED
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MEDBearishMed
01

Why it matters

Key trading inputs are the magnitude of revenue contraction driven by active earning coach declines, margin compression from lower volume and fixed-cost leverage, and management’s explicit loss and revenue guidance ranges for upcoming quarters.

02

Market read

This is a primary earnings-and-guidance disclosure with operating-metric detail (active earning coaches, revenue per coach) and forward ranges that can reprice expectations immediately.

03

What to watch

Catalyst program execution is expected to drive cost savings in Q3, and the company is debt-free with $169.8M cash and investments, which may reduce balance-sheet risk even if losses persist.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 3, 2026, ahead of the scheduled 4:30 p.m. ET conference call

Background

Medifast filed an 8-K with its Q2 2026 results (ended June 30, 2026) and provided updated outlook for Q3 and full-year 2026.

Company-level read

Ticker impact

$MEDBearishHigh confidence
Context

Medifast reported Q2 2026 results and guided Q3 revenue to $60M-$80M and Q3 EPS loss to $0.15-$0.65.

Expected impact

Near-term volatility likely around the guidance ranges and coach-count trajectory, with downside risk if active coach declines persist.

Evidence & confidence

The 8-K includes concrete financial prints (revenue, net loss) and forward guidance (Q3 and full-year 2026 revenue and EPS loss), which are direct inputs to valuation and expectations.

Market effects

Sector

Highlights ongoing demand and acquisition pressure for coach-led health and wellness models, with GLP-1 adoption cited as a headwind.

Regional

No specific regional spillover beyond company-level performance.

Global

Limited global relevance; primarily company-specific guidance and operating metrics.

Counterpoint

What could challenge this read

The company frames the quarter as part of a turnaround, citing sequentially stable revenue and rising revenue per active coach, which could offset coach-count declines if productivity improvements continue.

Key entities

  • public_company
    Medifast, Inc.

    Health and wellness company reporting Q2 2026 financial results and issuing Q3 and FY 2026 guidance.

  • product_brand
    Trilivy

    Brand referenced as part of the company’s 3.0 strategy and transformation.

  • cost_program
    Catalyst program

    Initiative designed to drive additional cost savings, with majority execution expected in Q3.

Read at source← All news

Related articles

AUG 4
$MEDHighAI 9/10

Why Medifast (MED) Stock Is Trading Up Today

Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.

financialcontent.com4 min
SEP 17
$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

yahoo.com2 min
SEP 17
$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

yahoo.com3 min
SEP 17
$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.

yahoo.com3 min
SEP 17
$LENMedAI 8/10

Lennar (LEN) Q3 2026 Earnings Call Transcript

Lennar (LEN) reported Q3 2026 net earnings of $284M, down 52% YoY, with GAAP EPS at $1.19. Revenues were $8B, driven by home sales. New orders and deliveries decreased due to affordability constraints. The company revised full-year delivery guidance to 80K-81K homes. Management cited higher interest rates and labor pressures as key challenges.

aol.com3 min